IOVANCE BIOTHERAPEUTICS, INC. Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of -$2.65 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2022-11-03
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2022-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2022-06-30 was -$2.65M.
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2020-12-31 was -$1.00K.
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2020-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2020 was -$284.00K.
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2019 was -$312.00K.
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2018 was -$223.00K.
- IOVANCE BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2017 was -$1.25M, a 295.02% decline from fiscal 2016.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month as first filed | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 6 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 9 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.65M derived: sum of 2 quarters · filed 2022-11-03 | -$2.65M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | -$2.65M 10-Q · filed 2022-08-04 | -$2.65M 10-Q · filed 2022-08-04 | ||||
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$1.00K derived: sum of 2 quarters · filed 2022-02-24 | -$166.00K derived: sum of 3 quarters · filed 2022-02-24 | -$284.00K 10-K · filed 2022-02-24 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$165.00K derived: sum of 2 quarters · filed 2021-11-04 | -$283.00K 10-Q · filed 2021-11-04 | -$402.00K derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | -$165.00K 10-Q · filed 2021-08-05 | -$283.00K 10-Q · filed 2021-08-05 | -$402.00K derived: sum of 3 quarters · filed 2022-02-24 | -$501.00K derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | -$118.00K 10-Q · filed 2021-05-06 | -$237.00K derived: sum of 2 quarters · filed 2022-02-24 | -$336.00K derived: sum of 3 quarters · filed 2022-02-24 | -$359.00K derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$218.00K derived: sum of 2 quarters · filed 2022-02-24 | -$241.00K derived: sum of 3 quarters · filed 2022-02-24 | -$312.00K 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$99.00K 10-Q · filed 2020-11-05 | -$122.00K derived: sum of 2 quarters · filed 2020-11-05 | -$193.00K 10-Q · filed 2020-11-05 | -$235.00K derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | -$23.00K 10-Q · filed 2020-08-06 | -$94.00K 10-Q · filed 2020-08-06 | -$136.00K derived: sum of 3 quarters · filed 2021-02-25 | -$195.00K derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | -$71.00K 10-Q · filed 2020-05-05 | $71.00K 10-Q · filed 2019-05-07 | -$113.00K derived: sum of 2 quarters · filed 2021-02-25 | -$172.00K derived: sum of 3 quarters · filed 2021-02-25 | -$234.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$101.00K derived: sum of 2 quarters · filed 2021-02-25 | -$163.00K derived: sum of 3 quarters · filed 2021-02-25 | -$223.00K 10-K · filed 2021-02-25 | $223.00K 10-K · filed 2019-02-28 | |
| 2018-09-30 | -$59.00K 10-Q · filed 2019-11-04 | -$121.00K derived: sum of 2 quarters · filed 2019-11-04 | -$181.00K 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | -$62.00K 10-Q · filed 2019-08-01 | -$122.00K 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | $60.00K 10-Q · filed 2019-05-07 | |||||
| 2017-12-31 | -$1.25M 10-K · filed 2020-02-25 | $1.25M 10-K · filed 2018-03-12 | ||||
| 2016-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $991.00K derived: sum of 2 quarters · filed 2019-02-28 | $642.00K 10-K · filed 2019-02-28 | -$642.00K 10-K · filed 2017-03-09 | ||
| 2016-09-30 | -$275.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$624.00K 10-Q · filed 2016-11-04 | ||||
| 2016-06-30 | -$349.00K 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |